More Videos
SPECIAL REPORT
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Wednesday's Economic News Crunch Could Tilt Markets
- The Social Media Gaming Threat
- NBA D-League On The Rise
- Obama Reiterates Commitment to Boost US-India Ties
- Japan Export Rebound Eases Fear of New Recession
- Australia Wheat Exporters Face Challenges: GrainCorp
- Stifling Anger at Work Can Kill, Survey Finds
- Citi Mortgage Reveals What Treasury Won't
- S&P to Hit 1,200 by Year-End: Chief Investor
- Amended Berkshire Hathaway Filing Indicates No Secret Stock Stakes at End of Q3
- Facebook's Biggest-Ever Holiday Shopping Season
- Facebook's New Dual Class Structure - Slow Steps to an IPO
- 5 Big Bank Stocks Investors Should Consider: Strategists
- Gambling Drunk, Texting to Live And America's On Sale - Your Emails
- Nov. 24: Unusual Volume Leaders
- NBA D-League On The Rise
- Sales of New Homes Forecast to Rise 2%
- Americans Ditch Planes for Trains this Thanksgiving
- Half of Banks' Losses May Still Be Hidden: IMF Head
- Obama Reiterates Commitment to Boost US-India Ties
- FDIC's Bair Cautions on Risks in Bank Break-Up Plan
- Wednesday's Economic News Crunch Could Tilt Markets
- Call Me Crazy: Confessions of a Black Friday Shopper
- Starbucks Eyes China as Next Major Market
- Citi Mortgage Reveals Something the US Treasury Won't
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
 |
CNBC.com |
SGP [SGP
Loading...
()
] and Merck [MRK
Loading...
()
] are joint-venture partners on the pill which is a combination of Zocor and Zetia. Critics have alleged officials may have delayed releasing what many perceive as the negative results of the clinical trial.
You can see the filing for yourself here, but this is the lowdown:
SGP says Chairman and CEO Fred Hassan was told about the results on January 10th at 8 a.m. by Tom Koestler, the head of SGP's Research Institute. According to the filing, an executive VP was told at the exact same time, another exec veep learned about it half an hour later, and yet another EVP half an hour after that. Koestler was the first top-level guy to get the results on Jan. 7th at 2 p.m. The companies publicly released the results on January 14th at 8:05 a.m. ET according to the time stamp on the wire services we subscribe to at CNBC.
The filing also explains why SGP is reporting earnings much later than Merck this quarter. Recently I blogged that this is the first time in recent memory that the partners didn't come out on the same day.
The company says the later than usual date, Feb. 12th, is "to allow time to properly prepare consolidated financial results reflecting technical 'purchase accounting' adjustments for the November 2007 acquisition of Organon BioSciences N.V."
The filing also mentions that "the integration (with Organon) is progressing well."
*ENHANCE is the acronym for the study that compared Merck and Schering's cholesterol fighter Vytorin (a combo of Zocor and Zetia) to Zocor--which is now available as a generic--alone.
UPDATE: Interesting political/pharmaceutical factoid my producer, Ruth, just came across on the Associated Press wire. In a story about John McCain's health, it mentions that he's taking Vytorin.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes